February 13, 2019, MedPage Today  

Treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) was associated with a "rapid and significant" decrease in risk for all-cause mortality and hepatocellular carcinoma (HCC), a French prospective study found. But the study could not clarify the long-term effects of these agents on liver decompensation. 

Read more.